Source study unconfirmed
Story checked
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting (opens in a new tab)
news-medical.net · 2026-11-05
Short answer
Source study unconfirmedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
Help improve NewsLink
Tell us what worked or what needs attention in this check.
The story
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
news-medical.net · 2026-11-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
View article claimsSearch result
Source study unconfirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
https://evaxion.ai/investors/press-releases/?press_release_id=11416
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedEvaxion will present new target-validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the ASH 2026 Annual Meeting.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedThe data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for AML by demonstrating broad patient coverage, conserved target expression across disease stages, and the induction of ERV-specific T-cell responses in humanized mice.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedThe new data build on preclinical findings presented at ASH 2025 that showed strong EVX-04-specific T-cell responses and inhibition of tumor growth in preclinical mouse models.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedEvaxion says EVX-04 targets non-conventional endogenous retrovirus tumor antigens from the dark genome, which it describes as selectively expressed in specific tumors but absent in normal tissue.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedThe company says the vaccine was designed from AML patient sequencing data and that all 16 ERV fragments included in EVX-04 elicit a specific immune response and prevent tumor growth in preclinical tumor models.View evidenceHide evidence
As stated16 ERV fragments
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedThe article says AML is an aggressive hematologic malignancy, most often seen in older adults, and notes that about 50% of patients are not fit for intensive treatment, with low-intensity chemotherapy as standard of care for that group.View evidenceHide evidence
As statedabout 50% of patients
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
Crossref, Europe PMC · 15 candidate papers
Expression of Human Endogenous Retrovirus (HERV-K) in Chronic Myeloid Leukemia
Leukemia & Lymphoma · 1993 · Crossref
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
2025 · Europe PMC
Correction: Yinzhihuang injection induces apoptosis and suppresses tumor growth in acute myeloid leukemia cells
PLOS ONE · 2025 · Crossref
A carcinogenic potency database of the standardized results of animal bioassays.
1984 · Europe PMC
BTN3A targeting in human Vg9Vd2 T cells-based anti-tumor immunotherapy : Application to Acute Myeloid Leukemia and pancreatic cancer
Crossref